Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer

Samsung Medical Center92 enrolled

Overview

To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Endometrial Cancer

Interventions

POHIM_EMRADIATION

hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed endometrioid type endometrial cancer * completion of hysterectomy and surgical staging * pathologically confirmed FIGO stage III * ECOG performance status 0 or 1 * adjuvant chemotherapy was done or planned Exclusion Criteria: * presence of distant metastasis * previous history of pelvic radiotherapy * severe and unstable medical condition * previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer

Locations (1)

Samsung Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

5-year disease-free survival rate

disease-free survival rate after the time of surgery

Time frame: 5 years

Secondary Outcomes

acute toxicities

acute toxicities within 3 months according to CTCAE v5.0

Time frame: 3 months

late toxicities

late toxicities according to CTCAE v5.0

Time frame: 5 years

Central Contacts

Won Park

CONTACT

+82-2-3410-2612 wonro.park@samsung.com

Won Kyung Cho

CONTACT

wklove.cho@samsung.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.